TriSleep™ Playbook — A Compliant Evening Functional-Food Line

Playbook scope: a from-0-to-1 delivery plan for an evening-routine functional-food line, built for brand owners and channel operators. This playbook publishes methods and definitions only — no efficacy claims. Specs, MOQs, and lead times below are indicative until confirmed in the technical documentation and a formal quote.

TriSleep™ is the ORAL sleep track within TONGNIAN's thirteen ™ product lines. Under the title "Oral Functional-Food Track from 0 to 1," Eight sections take the line from positioning to quoting. Every one stops at methods and definitions, never at performance promises.

01 · Market Positioning: The Evening-Routine Segment and the Format Opening

The problem this playbook solves: sleep-adjacent products force a choice between prescription weight and herbal vagueness — there is no compliant daily-ritual format carrying a new-material story with real documentation.

Sleep-adjacent products split into two camps. Prescription-grade aids carry dependency and compliance weight; herbal supplements are gentle but variable, and their ingredient stories are worn thin. Between the two sits an opening for a "daily-ritual" product: food-track compliant batch to batch, with a new-material narrative a channel can actually merchandise.

TriSleep™ fills that opening: fermented marine-derived EVs plus plant exosome fractions, pressed into a sublingual quick-dissolve tablet. Channel logic works backwards to format: cross-border e-commerce and evening-wellness gifting favour a 30-count jar (one month = one course = one gift box); pharmacy-adjacent retail favours blister singles for trial. Both tracks share one EV raw-material platform and one characterization baseline, so line extensions do not re-open development.

02 · Scientific Rationale: Oral EV Delivery and the Sublingual Choice

The design principle is cargo protection, not pharmacology. Exosomes are nanoscale vesicles that carry proteins, lipids, and microRNAs [1]; published human work on milk-derived exosomes showed that encapsulating a poorly bioavailable polyphenol (ellagic acid) inside exosomes measurably improved its oral bioavailability over a two-week intervention (Molecular Nutrition & Food Research, 2026) [3]. EVs act as delivery vehicles that shield cargo through the digestive environment — the reason an oral EV system is a credible functional-food chassis rather than a novelty.

Route is the second design variable. Sublingual absorption partially bypasses first-pass metabolism. Just as important for an evening program, the tablet removes the water-and-prep friction that erodes nightly adherence. The functional-food framing is deliberate: the product competes on format consistency and material documentation, while functional claims, where a market allows them, ride the local filing rather than the label's imagination.

Fig. 1 — Route schematic: the sublingual format removes preparation friction and partially bypasses first-pass metabolism via buccal absorption.

03 · Formulation Design: The Dual-Source EV Family

Three formulation decisions define the track:

1. Dual-source EV system. Fermented marine-derived EVs (scalable and standardizable at the fermentation upstream) co-formulated with plant exosome fractions — one characterization baseline across the whole family, so tablets, liquids, and stick packs are siblings, not separate projects.
2. Quick-dissolve base. Sugar-free, neutral evening flavour; dissolves on the tongue in seconds. Adherence lives or dies on format — so the format is engineered first: it dissolves in seconds, no water, no prep.
3. Format family on one baseline. Flagship: 30-count sublingual jar. Extensions: oral liquid / drops for liquid-preferring markets, single-serve lyophilized stick packs for tea-style rituals. Each format ships with a specification card (fill, packaging, stability plan — values per the technical agreement).

04 · Process: From Closed Micro-Batch to Finished Tablet

1. EV material production — the fully enclosed 0.5–5 L micro-batch line: seed revival and expansion in closed tubing, scheduled harvest, tangential-flow separation and concentration (NuoqTFF 1.0 mother unit), sterile filtration; retain samples kept between batches. The downstream train layout follows published industrial guidance [4].
2. Co-formulation — marine EVs blended with plant exosome fractions; payload and stability checked on retained samples against the characterization baseline.
3. Finished-goods manufacture — tablet compression or liquid filling under food-grade GMP, with the EV baseline documentation attached to each production lot.
4. Batch release — COA and batch records per batch; retain-sample plan as standard.

05 · QC & Characterization: Batch-Release Test Panel

Panel design follows MISEV2018 [2] and the national measurement guideline [5].

06 · Regulatory Pathway: US & EU Supplement Frameworks

The track is engineered for US and EU market entry first. In the US, the line is positioned as a dietary supplement under FDA's DSHEA framework — structure/function-style label discipline with the standard disclaimer, and ingredient documentation that stands up to FDA review. In the EU, oral formats route through the food-supplement framework, with novel-food assessment where ingredient history requires it. The material line holds FDA DMF Type II 044197 and INCI 41316 documentation — depth most supplement-shelf competitors cannot show, and leverage for premium pricing.

Claims discipline is written into the playbook: format and ritual language on pack ("quick-dissolve," "evening ritual," "30-day course"); functional claims only within what the destination-market framework authorizes (US structure/function rules, EU permitted-claims lists). The compliance team tracks FDA and EFSA movements and shares updates at playbook review points. For China market entry later, the blue-hat functional-food route is an additional option on the same base formula.

Documentation comparison (what diligence actually checks)

Market-supplier column reflects qualitative channel observation, not a named comparison.

07 · Expected Program Outcomes: Framing & Evidence Level

• Adherence is the design goal. A 30-count jar is a one-month course; the program metric is ritual consistency, not promises. The quick-dissolve format exists because consistency is the hard part of any evening program.
• Perceived wind-down support is tracked in TONGNIAN's internal observational programs. Published oral-EV bioavailability work supports the delivery design [3]; it does not license therapeutic claims. Supporting observational evidence is available to partners: internal evening-program pilot cohorts, 2025–2026, under NDA [6].
• No claims are made regarding sleep onset, duration, or any physiological outcome outside the authorized filing scope. Authority comes from documentation, batch measurement, and format honesty.

08 · MOQ & Lead-Time Framework (indicative) (indicative)

State your stage — sampling, pilot, or production — in the /contact/ form and the quotation follows the same structure, so RFQs map directly to these tiers.

References

1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
2. Théry C, Witwer KW, et al. MISEV2018: minimal information for studies of extracellular vesicles — a position paper of the ISEV. J Extracell Vesicles. 2018;7(1):1535750.
3. Ávila-Gálvez MÁ, et al. Oral delivery of ellagic acid encapsulated in milk exosomes: bioavailability, urolithin production, and gut microbiota modulation. Mol Nutr Food Res. 2026.
4. Cobetter. Exosomes Part I: Applications and Downstream Processing Overview. Technical review, 2025.
5. Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17), national standard — TONGNIAN, drafting organization.
6. TONGNIAN. Internal observational data — evening-program pilot cohorts, 2025–2026 (partner access under NDA).